J&J(US:JNJ) Youtube·2025-10-03 20:00Core Viewpoint - Johnson & Johnson's shares reached an all-time high following an upgrade from Wells Fargo, which raised its price target to $212 from $170, citing potential upside in its pharmaceutical business and reduced tariff and pricing risks [1]. Company Performance - Johnson & Johnson's stock is currently viewed as an attractive entry point due to its valuation [2]. - The company's performance is aligning with the broader S&P 500, while it is outperforming the pharmaceutical ETF [3]. - The stock has shown a strong upward trend, with a notable bull flag pattern indicating bullish sentiment among traders [9]. Market Context - The healthcare sector overall is facing challenges, with a decline of 4.1% this year, attributed to legislative risks [4]. - Distributors like McKesson and Cardinal Health are performing well, while managed care companies are struggling [5][6]. - Recent news regarding competitors, such as Humana and Pfizer, has contributed to a volatile market environment [7][8]. Technical Analysis - Johnson & Johnson's stock has seen a significant rally from a low of approximately $174-$175, with a recent breakout above previous highs near $181 [10]. - Current trading levels are around $189.10, with a potential upside target near $190.60 [12]. - The expected move for the stock over the next 14 days is about 3.9%, indicating relatively low volatility [14]. Options Activity - There has been notable activity in the October 17th 175 calls, indicating interest from traders [15]. - A significant bearish opening trade was observed for June 18th 190 strike puts, suggesting some traders are anticipating a decline [16].